TNF and rheumatoid arthritis: Specifically, non-steroidal anti-inflammatory drugs, glucocorticoids [93], and DMARDs of synthetic origin (i.e., methotrexate or janus kinase (JAK)-inhibitors) or of biological origin (i.e., TNF inhibitors, costimulation modifiers, IL-6 inhibitors and B-cell-depleting drugs) are included in the first-line protocols for RA patients [94,95].